Voquezna (vonoprazan) dosing, indications, interactions, adverse effects, and more (original) (raw)
All Interactions Sort By:
Contraindicated (1)
- rilpivirine
vonoprazan will decrease the level or effect of rilpivirine by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated.
Serious (40)
- amobarbital
amobarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - apalutamide
apalutamide will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - armodafinil
armodafinil will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - atazanavir
vonoprazan will decrease the level or effect of atazanavir by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - belzutifan
belzutifan will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - bexarotene
bexarotene will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - bosentan
bosentan will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - butabarbital
butabarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - butalbital
butalbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - carbamazepine
carbamazepine will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - cenobamate
cenobamate will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - dabrafenib
dabrafenib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - dasatinib
vonoprazan will decrease the level or effect of dasatinib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - efavirenz
efavirenz will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - elagolix
elagolix will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - encorafenib
encorafenib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - enzalutamide
enzalutamide will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - erlotinib
vonoprazan will decrease the level or effect of erlotinib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - eslicarbazepine acetate
eslicarbazepine acetate will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - etravirine
etravirine will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - fosphenytoin
fosphenytoin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - ivosidenib
ivosidenib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - lorlatinib
lorlatinib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - lumacaftor/ivacaftor
lumacaftor/ivacaftor will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - mavacamten
mavacamten will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - mitapivat
mitapivat will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - mitotane
mitotane will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - modafinil
modafinil will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - nafcillin
nafcillin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - nelfinavir
vonoprazan will decrease the level or effect of nelfinavir by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - pentobarbital
pentobarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - pexidartinib
pexidartinib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - phenobarbital
phenobarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - phenytoin
phenytoin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - primidone
primidone will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - rifabutin
rifabutin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - rifampin
rifampin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - rifapentine
rifapentine will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - sotorasib
sotorasib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - St John's Wort
St John's Wort will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
Monitor Closely (42)
- alfentanil
vonoprazan will increase the level or effect of alfentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - carbamazepine
vonoprazan will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - carbonyl iron
vonoprazan will decrease the level or effect of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - cilostazol
vonoprazan will increase the level or effect of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Reduce cilostazol dose to 50 mg BID when coadministered with strong or moderate inhibitors of CYP2C19. - citalopram
vonoprazan will increase the level or effect of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. - clonidine
vonoprazan will increase the level or effect of clonidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - clopidogrel
vonoprazan will decrease the level or effect of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Vonoprazan may reduce plasma concentrations of the active metabolite of clopidogrel and may cause reduction in platelet inhibition. - colchicine
vonoprazan will increase the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - cyclosporine
vonoprazan will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - dihydroergotamine
vonoprazan will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - disopyramide
vonoprazan will increase the level or effect of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - ergotamine
vonoprazan will increase the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - ethosuximide
vonoprazan will increase the level or effect of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - everolimus
vonoprazan will increase the level or effect of everolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - fentanyl
vonoprazan will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - ferric carboxymaltose
vonoprazan will decrease the level or effect of ferric carboxymaltose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric citrate
vonoprazan will decrease the level or effect of ferric citrate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric derisomaltose
vonoprazan will decrease the level or effect of ferric derisomaltose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric gluconate
vonoprazan will decrease the level or effect of ferric gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric maltol
vonoprazan will decrease the level or effect of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric pyrophosphate DIALYSATE
vonoprazan will decrease the level or effect of ferric pyrophosphate DIALYSATE by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric pyrophosphate IV
vonoprazan will decrease the level or effect of ferric pyrophosphate IV by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferrous fumarate
vonoprazan will decrease the level or effect of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferrous gluconate
vonoprazan will decrease the level or effect of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferrous sulfate
vonoprazan will decrease the level or effect of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferumoxytol
vonoprazan will decrease the level or effect of ferumoxytol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - iron dextran complex
vonoprazan will decrease the level or effect of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - iron sucrose
vonoprazan will decrease the level or effect of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - itraconazole
vonoprazan will decrease the level or effect of itraconazole by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Closely monitor for reduced itraconazole efficacy if combined. Itraconazole capsules only: Separate administration by at least 1 hr before or 2 hr after ketoconazole. - ketoconazole
vonoprazan will decrease the level or effect of ketoconazole by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate administration by at least 1 hr before or 2 hr after ketoconazole. - midazolam
vonoprazan will increase the level or effect of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - mycophenolate
vonoprazan will decrease the level or effect of mycophenolate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Enteric-coated mycophenolate sodium may be less sensitive to this interaction. - pacritinib
vonoprazan will increase the level or effect of pacritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - pimozide
vonoprazan will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - polysaccharide iron
vonoprazan will decrease the level or effect of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - quinidine
vonoprazan will increase the level or effect of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - quinine
vonoprazan will increase the level or effect of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - repaglinide
vonoprazan will increase the level or effect of repaglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - sirolimus
vonoprazan will increase the level or effect of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - tacrolimus
vonoprazan will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - theophylline
vonoprazan will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - triazolam
vonoprazan will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates.
Minor (0)
- alfentanil
Monitor Closely (1)vonoprazan will increase the level or effect of alfentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - amobarbital
Serious - Use Alternative (1)amobarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - apalutamide
Serious - Use Alternative (1)apalutamide will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - armodafinil
Serious - Use Alternative (1)armodafinil will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - atazanavir
Serious - Use Alternative (1)vonoprazan will decrease the level or effect of atazanavir by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - belzutifan
Serious - Use Alternative (1)belzutifan will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - bexarotene
Serious - Use Alternative (1)bexarotene will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - bosentan
Serious - Use Alternative (1)bosentan will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - butabarbital
Serious - Use Alternative (1)butabarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - butalbital
Serious - Use Alternative (1)butalbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - carbamazepine
Monitor Closely (1)vonoprazan will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates.Serious - Use Alternative (1)carbamazepine will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - carbonyl iron
Monitor Closely (1)vonoprazan will decrease the level or effect of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - cenobamate
Serious - Use Alternative (1)cenobamate will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - cilostazol
Monitor Closely (1)vonoprazan will increase the level or effect of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Reduce cilostazol dose to 50 mg BID when coadministered with strong or moderate inhibitors of CYP2C19. - citalopram
Monitor Closely (1)vonoprazan will increase the level or effect of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. - clonidine
Monitor Closely (1)vonoprazan will increase the level or effect of clonidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - clopidogrel
Monitor Closely (1)vonoprazan will decrease the level or effect of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Vonoprazan may reduce plasma concentrations of the active metabolite of clopidogrel and may cause reduction in platelet inhibition. - colchicine
Monitor Closely (1)vonoprazan will increase the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - cyclosporine
Monitor Closely (1)vonoprazan will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - dabrafenib
Serious - Use Alternative (1)dabrafenib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - dasatinib
Serious - Use Alternative (1)vonoprazan will decrease the level or effect of dasatinib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - dihydroergotamine
Monitor Closely (1)vonoprazan will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - disopyramide
Monitor Closely (1)vonoprazan will increase the level or effect of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - efavirenz
Serious - Use Alternative (1)efavirenz will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - elagolix
Serious - Use Alternative (1)elagolix will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - encorafenib
Serious - Use Alternative (1)encorafenib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - enzalutamide
Serious - Use Alternative (1)enzalutamide will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - ergotamine
Monitor Closely (1)vonoprazan will increase the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - erlotinib
Serious - Use Alternative (1)vonoprazan will decrease the level or effect of erlotinib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - eslicarbazepine acetate
Serious - Use Alternative (1)eslicarbazepine acetate will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - ethosuximide
Monitor Closely (1)vonoprazan will increase the level or effect of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - etravirine
Serious - Use Alternative (1)etravirine will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - everolimus
Monitor Closely (1)vonoprazan will increase the level or effect of everolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - fentanyl
Monitor Closely (1)vonoprazan will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - ferric carboxymaltose
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric carboxymaltose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric citrate
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric citrate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric derisomaltose
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric derisomaltose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric gluconate
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric maltol
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric pyrophosphate DIALYSATE
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric pyrophosphate DIALYSATE by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferric pyrophosphate IV
Monitor Closely (1)vonoprazan will decrease the level or effect of ferric pyrophosphate IV by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferrous fumarate
Monitor Closely (1)vonoprazan will decrease the level or effect of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferrous gluconate
Monitor Closely (1)vonoprazan will decrease the level or effect of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferrous sulfate
Monitor Closely (1)vonoprazan will decrease the level or effect of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - ferumoxytol
Monitor Closely (1)vonoprazan will decrease the level or effect of ferumoxytol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - fosphenytoin
Serious - Use Alternative (1)fosphenytoin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - iron dextran complex
Monitor Closely (1)vonoprazan will decrease the level or effect of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - iron sucrose
Monitor Closely (1)vonoprazan will decrease the level or effect of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - itraconazole
Monitor Closely (1)vonoprazan will decrease the level or effect of itraconazole by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Closely monitor for reduced itraconazole efficacy if combined. Itraconazole capsules only: Separate administration by at least 1 hr before or 2 hr after ketoconazole. - ivosidenib
Serious - Use Alternative (1)ivosidenib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - ketoconazole
Monitor Closely (1)vonoprazan will decrease the level or effect of ketoconazole by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate administration by at least 1 hr before or 2 hr after ketoconazole. - lorlatinib
Serious - Use Alternative (1)lorlatinib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - lumacaftor/ivacaftor
Serious - Use Alternative (1)lumacaftor/ivacaftor will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - mavacamten
Serious - Use Alternative (1)mavacamten will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - midazolam
Monitor Closely (1)vonoprazan will increase the level or effect of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - mitapivat
Serious - Use Alternative (1)mitapivat will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - mitotane
Serious - Use Alternative (1)mitotane will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - modafinil
Serious - Use Alternative (1)modafinil will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - mycophenolate
Monitor Closely (1)vonoprazan will decrease the level or effect of mycophenolate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Enteric-coated mycophenolate sodium may be less sensitive to this interaction. - nafcillin
Serious - Use Alternative (1)nafcillin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - nelfinavir
Serious - Use Alternative (1)vonoprazan will decrease the level or effect of nelfinavir by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. - pacritinib
Monitor Closely (1)vonoprazan will increase the level or effect of pacritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - pentobarbital
Serious - Use Alternative (1)pentobarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - pexidartinib
Serious - Use Alternative (1)pexidartinib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - phenobarbital
Serious - Use Alternative (1)phenobarbital will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - phenytoin
Serious - Use Alternative (1)phenytoin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - pimozide
Monitor Closely (1)vonoprazan will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - polysaccharide iron
Monitor Closely (1)vonoprazan will decrease the level or effect of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. - primidone
Serious - Use Alternative (1)primidone will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - quinidine
Monitor Closely (1)vonoprazan will increase the level or effect of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - quinine
Monitor Closely (1)vonoprazan will increase the level or effect of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - repaglinide
Monitor Closely (1)vonoprazan will increase the level or effect of repaglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - rifabutin
Serious - Use Alternative (1)rifabutin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - rifampin
Serious - Use Alternative (1)rifampin will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - rifapentine
Serious - Use Alternative (1)rifapentine will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - rilpivirine
Contraindicated (1)vonoprazan will decrease the level or effect of rilpivirine by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. - sirolimus
Monitor Closely (1)vonoprazan will increase the level or effect of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - sotorasib
Serious - Use Alternative (1)sotorasib will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - St John's Wort
Serious - Use Alternative (1)St John's Wort will decrease the level or effect of vonoprazan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - tacrolimus
Monitor Closely (1)vonoprazan will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - theophylline
Monitor Closely (1)vonoprazan will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates. - triazolam
Monitor Closely (1)vonoprazan will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Vonoprazan is weak CYP3A inhibitor. Caution with sensitive CYP3A substrates.